title: Impaired androgen production in female adolescents and young adults after total body irradiation prior to BMT in childhood.
abstract: Pubertal development and androgen production were evaluated 1-10 years after bone marrow transplantation (BMT) in 15 females aged 14-23 (mean 17) years. Before BMT, these patients had received combination chemotherapy for hematologic malignancy, and all had had a transplant program including total body irradiation (TBI). Of the nine patients who were pre-menarcheal at BMT, two had subsequently experienced spontaneous menarche at 11.5 and 13.3 years of age. Six were post-menarcheal, but became amenorrheic after BMT. Menstruation subsequently started spontaneously in one of them 6 years after BMT. At the time of the study, three patients were early to mid-pubertal and 12 late pubertal or post-pubertal. Twelve patients were receiving sex steroid substitution therapy. Serum concentrations of testosterone, androstenedione, dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS) were determined. Androgen levels of late pubertal and post-pubertal transplanted patients were compared with 19 post-menarcheal patients aged 14-21 (mean 17) years who had been treated for hematologic malignancy with conventional chemotherapy. Testosterone levels of 52 healthy post-menarcheal females aged 14-29 (mean 19) years were measured as controls. Androgen levels of the BMT patients were lower than those of the conventionally treated patients. Differences in testosterone, androstenedione and DHEA levels were significant. Three spontaneously menstruating BMT patients had normal androgen levels. Testosterone levels of the conventionally treated patients and healthy controls were similar. Subnormal androgen production might be one factor behind the problems in pubertal development and sex life experienced by females after BMT. The use of these hormone levels for follow-up purposes and the potential value of androgen replacement therapy in females after TBI merit further study.
authors.affiliation: Children's Hospital, University of Helsinki, Finland.
authors.forename: L
authors.initials: L
authors.lastname: Hovi
authors.forename: P
authors.initials: P
authors.lastname: Tapanainen
authors.forename: U M
authors.initials: UM
authors.lastname: Saarinen-Pihkala
authors.forename: M A
authors.initials: MA
authors.lastname: Siimes
mesh_terms: D000293:Adolescent; D000328:Adult; D000728:Androgens / Q000097:blood*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D019337:Hematologic Neoplasms / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D011627:Puberty / Q000097:blood; D013997:Time Factors; D014916:Whole-Body Irradiation
chemical_list: D000728:Androgens